Understanding side effects of therapy for myasthenia gravis and their impact on daily life

BMC Neurology

Table 1 Refractory* status classifications for Phase 2 Post-hoc analysis

	Previous use of at least two immunosuppressive treatments	Current use of immunosuppressive treatment	Use of IVIg and/or plasmapheresis on more than four separate occasions over the past year
Refractory with IVIg	Yes	Yes	Yes
	Yes	No	Yes
	No	Yes	Yes
Refractory without IVIg	Yes	Yes	No
Refractory without IVIg	Yes	No	No
Non-refractory	No	Yes	No

^*Refractory = MG post-intervention status unchanged since initiation of treatment
IVIg, intravenous immunoglobulin

ISSN: 1471-2377